Laddar...
Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemia
Mortality remains high in septic shock with few new treatment options. Angiotensin II has been recently approved for use in septic shock due to promising results in the ATHOS-3 trial. However, patients with neutropenia were excluded in the trial. This patient population is becoming increasingly comm...
Sparad:
| I publikationen: | BMJ Case Rep |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BMJ Publishing Group
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7322323/ https://ncbi.nlm.nih.gov/pubmed/32595128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-233432 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|